Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Shares Issued (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Shares Issued for 15 consecutive years, with $16.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Issued changed N/A to $16.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $19.6 million, a 18578.1% increase, with the full-year FY2024 number at $7.3 million, up 626.5% from a year prior.
  • Shares Issued was $16.8 million for Q3 2025 at Plus Therapeutics, up from $1.9 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $16.8 million in Q3 2025 to a low of -$2.3 million in Q3 2023.
  • A 4-year average of $3.6 million and a median of $1.2 million in 2023 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 4296.77% in 2023; the steepest drop was 133.05% in 2023.
  • Plus Therapeutics' Shares Issued stood at $7.2 million in 2021, then plummeted by 91.64% to $600000.0 in 2022, then soared by 66.67% to $1.0 million in 2023, then soared by 1581.7% to $16.8 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Shares Issued are $16.8 million (Q3 2025), $1.9 million (Q2 2025), and $882000.0 (Q1 2025).